New topical psoriasis treatment launched

Wynzora (calcipotriol/betamethasone) is the first cream formulation of a vitamin D/corticosteroid combination.

Close-up of a person's fingers applying a white cream to a red, scaly, raised patch of psoriasis on their elbow.
Wynzora cream is a topical treatment for psoriasis, designed for rapid skin absorption. | GETTY IMAGES

Wynzora is indicated for topical treatment of mild to moderate psoriasis vulgaris, including scalp psoriasis, in adults. It is applied once daily for up to 8 weeks. One gram of Wynzora contains 50 microgram calcipotriol (as hydrate) and 500 microgram betamethasone (as dipropionate).

Wynzora uses a proprietary formulation technology that the manufacturer says allows oil and water to be mixed into a cream using smaller amounts of surfactants than conventional emulsions. It is designed to be absorbed quickly, to encourage patient adherence. 

Treatment success

In a pooled analysis of two phase III, multicentre, randomised, investigator-blind trials in patients with mild to moderate psoriasis (n=1271), the calcipotriol/betamethasone cream showed superior efficacy and comparable safety to calcipotriol/betamethasone gel.

After 8 weeks of once-daily treatment, the rate of treatment success as determined by the Physician's Global Assessment (PGA) score was greater in patients treated with the cream than those treated with the gel (43.2% vs 31.9%; p<0.0001). Statistically significant differentiation between the cream and the gel was observed as early as week 4 (p=0.0001) and maintained up to week 8.

Patients treated with the cream also showed a greater mean reduction in modified Psoriasis Area and Severity Index (mPASI) score at week 8 than those who used the gel: 64.6% versus 56.4% (p<0.0001). The difference in treatment effect between the cream and the gel reached statistical significance as early as week 1 (p=0.0009) and was maintained at weeks 4 (p<0.0001) and 6.

In addition, calcipotriol/betamethasone cream was associated with greater improvement in quality of life than calcipotriol/betamethasone gel. A Dermatology Life Quality Index score of 0 or 1, meaning that psoriasis had no effect at all on the patient's life, was achieved by 43.8% of patients in the cream group versus 34.2% of those in the gel group at week 8 (p=0.0005).

There were no statistically significant differences between the treatment arms in the proportion of patients experiencing a treatment-emergent adverse effect. All adverse reactions in the calcipotriol/betamethasone cream arm occurred at a frequency of less than 1%.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in